More than 20 billion dollars worth of biopharmaceuticals are scheduled to go off-patent by 2006. Given the strong political impetus and the development of technological tools that can answer the questions regulatory authorities may raise, it is inevitable that the FDA and EMEA will allow biogeneric or biosimilar products. Even with all the regulato
Koop dit e-boek en ontvang er nog 1 GRATIS!
Taal Engels ● Formaat PDF ● Pagina’s 584 ● ISBN 9781420037937 ● Uitgeverij CRC Press ● Gepubliceerd 2002 ● Downloadbare 3 keer ● Valuta EUR ● ID 5697838 ● Kopieerbeveiliging Adobe DRM
Vereist een DRM-compatibele e-boeklezer